section name header

Pronunciation

is-RA-di-peen

Classifications

Therapeutic Classification: antianginals, antihypertensives

Pharmacologic Classification: calcium channel blockers

Indications

REMS


Action

  • Inhibits the transport of calcium into myocardial and vascular smooth muscle cells, resulting in inhibition of excitation-contraction coupling and subsequent contraction.
Therapeutic effects:
  • Systemic vasodilation resulting in decreased BP.

Pharmacokinetics

Absorption: Well absorbed following oral administration but extensively metabolized, resulting in bioavailability.

Distribution: Unknown.

Protein Binding: 95%.

Metabolism/Excretion: Completely metabolized by the liver.

Half-Life: 8 hr.

Time/Action Profile

(antihypertensive effects)
ROUTEONSETPEAKDURATION
PO<2 hr2–3 hr12 hr



For single doses, maximal antihypertensive effect during chronic dosing may take 2–4 wk.



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: peripheral edema, HF, ARRHYTHMIAS, bradycardia, chest pain, hypotension, palpitations, syncope, tachycardia

Derm: dermatitis, erythema multiforme, flushing, photosensitivity, pruritus/urticaria, rash, STEVENS-JOHNSON SYNDROME, sweating

EENT: blurred vision, disturbed equilibrium, epistaxis, tinnitus

Endo: gynecomastia, hyperglycemia

GI: liver enzymes, anorexia, constipation, diarrhea, dry mouth, dyspepsia, nausea, vomiting

GU: dysuria, nocturia, polyuria, sexual dysfunction, urinary frequency

Hemat: anemia, leukopenia, thrombocytopenia

Metab: weight

MS: joint stiffness, muscle cramps

Neuro: abnormal dreams, anxiety, confusion, dizziness, drowsiness, dysgeusia, headache, nervousness, paresthesia, psychiatric disturbances, tremor, weakness

Resp: cough, dyspnea

Misc: gingival hyperplasia

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

DynaCirc